Sjögren's disease & overlap diseases
Clinical, biological, prognostic characteristics of patients with immune-mediated thrombotic thrombocytopenic purpura and Sjögren’s disease
Authors' conclusion
iTTP can be a rare complication in patients with SjD.
Study context
- Population
- Patients with immune-mediated thrombotic thrombocytopenic purpura and Sjögren disease (SjD), French TTP Registry
- Participants
- 30 / 65 / 45
- Exposure
- iTTP-SjD vs primary SjD (pSjD) and vs idiopathic iTTP
- iTTP-SjDn = 30
- pSjDn = 65reference
- Idiopathic iTTPn = 45reference
- Outcome
- Characteristics of iTTP-SjD vs pSjD
Methodological detailsregistry-based, two control groups
- Registry-based
- Two control groups
Main finding
As reported in the abstract
- iTTP-SjD diagnosed with SjD at the time of iTTP diagnosis
- 18
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Mortality and iTTP relapses, iTTP-SjD vs idiopathic iTTPiTTP-SjD vs idiopathic iTTP · comparable | log-rank tests, p=0.228 |
| Mortality and iTTP relapses, iTTP-SjD vs idiopathic iTTPiTTP-SjD vs idiopathic iTTP · comparable | multivariate analysis, p=0.181 |
Mortality and iTTP relapses, iTTP-SjD vs idiopathic iTTP
- Short-term outcomes (survival at day 30, relapse) were favourable
Treatments in iTTP-SjD
- Plasma exchange
- 28
- Rituximab
- 19
- Caplacizumab
- 3
- Corticosteroids
Original publication
Clinical, biological, prognostic characteristics of patients with immune-mediated thrombotic thrombocytopenic purpura and Sjögren’s disease. RMD Open. Published 29 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →